According to study guidelines, crizotinib is recommended as a first-line treatment for locally advanced or metastatic ALK positive NSCLC.[20] Although many fusion partners of ALK have been found in lung cancer, not all fusion mutations respond to crizotinib, such as CMTR1-ALK, which was reported has no response to crizotinib. The gene discussed is ALK; the disease is non-small cell lung carcinoma.